Immusoft

Immusoft is a cell therapy company focused on developing new treatments for rare diseases by using the continuous delivery of therapeutic proteins derived from the patient's own cells. The company is developing a technology platform called Immune System Programming (ISP™), which can modify patients' B cells and instruct them to produce gene-encoded drugs. B cells reprogrammed with ISP become miniature drug factories, expected to survive in the patient’s body and provide years of therapeutic benefits.